# US 2004/0071684 A1 · Use of galectin-3 and galectin-7 to promote the re-epithelialization of wounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0071684 A1
- Document ID: US20040071684A1
- Status: Published application
- Kind: A1
- Application number: 10/133,234
- Filed: 2002-04-26
- Published: 2004-04-15
- Earliest claimed: 2001-04-27
- Assignees: Trustees of Tufts College
- Inventors: Noorjahan Panjwani; Zhiyi Cao
- Web page: https://patentgrep.com/patent/US20040071684A1

## CPC

- A61K 38/1709: {from mammals}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Methods for the therapeutic treatment of epithelial wounds in mammals comprising administering to a mammal afflicted with an epithelial wound a therapeutically effective amount of a galectin-3 protein and/or a galectin-7 protein are provided. Pharmaceutical compositions comprising a pharmaceutically suitable carrier or diluent and as an active agent a galectin-3 protein and/or a galectin-7 protein are also provided.

## Claims

### Claim 1

A method for the therapeutic treatment of epithelial wounds in mammals comprising administering to a mammal afflicted with an epithelial wound a therapeutically effective amount of a galectin-3 protein.

### Claim 2

A method for the therapeutic treatment of epithelial wounds in mammals comprising administering to a mammal afflicted with an epithelial wound a therapeutically effective amount of a galectin-7 protein.

### Claim 3 (depends on 1, 2)

The method according to claim 1 or 2, wherein said epithelial wound is a persistent epithelial defect or a recurrent epithelial erosion.

### Claim 4 (depends on 1, 2)

The method according to claim 1 or 2, wherein said epithelial wound is an epithelial lesion or an epithelial erosion.

### Claim 5 (depends on 1, 2)

The method according to claim 1 or 2, wherein said epithelial wound is selected from the group consisting of ulcers, blisters, bums, sores, boils, cuts, abrasions, and lacerations.

### Claim 6 (depends on 1, 2)

The method according to claim 1 or 2, wherein said epithelial wound is a corneal wound.

### Claim 7 (depends on 6)

The method according to claim 6, wherein said corneal wound is a persistent corneal defect or a recurrent corneal erosion.

### Claim 8 (depends on 6)

The method according to claim 6, wherein said corneal wound was caused by excimer laser keratectomy.

### Claim 9 (depends on 1, 2)

The method according to claim 1 or 2, wherein said epithelial wound is a skin wound or a wound to the gastrointestinal tract.

### Claim 10 (depends on 1)

The method of claim 1, wherein the galectin-3 protein includes the amino acid sequence of SEQ ID NO:1.

### Claim 11 (depends on 1)

The method of claim 1, wherein the galectin-3 protein includes an amino acid sequence that is substantially identical to the amino acid sequence of SEQ ID NO:1.

### Claim 12 (depends on 1)

The method of claim 1, wherein the galectin-3 protein includes a galectin-3 N-terminal domain and a galectin-3 proline, glycine, and tyrosine-rich domain.

### Claim 13 (depends on 1)

The method of claim 1, wherein the galectin-3 protein includes a galectin-3 proline, glycine, and tyrosine-rich domain and a galectin-3 galactoside-binding domain.

### Claim 14 (depends on 1)

The method of claim 1, wherein the galectin-3 protein includes a galectin-3 galactoside-binding domain.

### Claim 15 (depends on 2)

The method of claim 2, wherein the galectin-7 protein includes the amino acid sequence of SEQ ID NO:2.

### Claim 16 (depends on 2)

The method of claim 2, wherein the galectin-7 protein includes an amino acid sequence that is substantially identical to the amino acid sequence of SEQ ID NO:2.

### Claim 17 (depends on 2)

The method of claim 2, wherein the galectin-7 protein includes a galectin-7 galactoside-binding domain.

### Claim 18

A pharmaceutical composition having a promoting effect on the re-epithelialization of a wound, said composition comprising a pharmaceutically suitable carrier or diluent and an amount of a galectin-3 protein sufficient to promote the re-epithelialization of said wound.

### Claim 19

A pharmaceutical composition having a promoting effect on the re-epithelialization of a wound, said composition comprising a pharmaceutically suitable carrier or diluent and an amount of a galectin-7 protein sufficient to promote the re-epithelialization of said wound.

### Claim 20 (depends on 18, 19)

The pharmaceutical composition of claim 18 or 19, wherein said wound is a persistent epithelial defect or a recurrent epithelial erosion.

### Claim 21 (depends on 18, 19)

The pharmaceutical composition of claim 18 or 19, wherein said wound is an epithelial lesion or an epithelial erosion.

### Claim 22 (depends on 18, 19)

The pharmaceutical composition of claim 18 or 19, wherein said wound is selected from the group consisting of ulcers, blisters, bums, sores, boils, cuts, abrasions, and lacerations.

### Claim 23 (depends on 18, 19)

The pharmaceutical composition of claim 18 or 19, wherein said wound is a corneal wound.

### Claim 24 (depends on 23)

The pharmaceutical composition of claim 23, wherein said corneal wound is a persistent corneal defect or a recurrent corneal erosion.

### Claim 25 (depends on 23)

The pharmaceutical composition of claim 23, wherein said corneal wound was caused by excimer laser keratectomy.

### Claim 26 (depends on 18, 19)

The pharmaceutical composition of claim 18 or 19, wherein said wound is a skin wound or a wound to the gastrointestinal tract.

### Claim 27 (depends on 18)

The pharmaceutical composition of claim 18, wherein the galectin-3 protein includes the amino acid sequence of SEQ ID NO:1.

### Claim 28 (depends on 18)

The pharmaceutical composition of claim 18, wherein the galectin-3 protein includes an amino acid sequence that is substantially identical to the amino acid sequence of SEQ ID NO:1.

### Claim 29 (depends on 18)

The pharmaceutical composition of claim 18, wherein the galectin-3 protein includes a galectin-3 N-terminal domain and a galectin-3 proline, glycine, and tyrosine-rich domain.

### Claim 30 (depends on 18)

The pharmaceutical composition of claim 18, wherein the galectin-3 protein includes a galectin-3 proline, glycine, and tyrosine-rich domain and a galectin-3 galactoside-binding domain.

### Claim 31 (depends on 18)

The pharmaceutical composition of claim 18, wherein the galectin-3 protein includes a galectin-3 galactoside-binding domain.

### Claim 32 (depends on 19)

The pharmaceutical composition of claim 19, wherein the galectin-7 protein includes the amino acid sequence of SEQ ID NO:2.

### Claim 33 (depends on 19)

The pharmaceutical composition of claim 19, wherein the galectin-7 protein includes an amino acid sequence that is substantially identical to the amino acid sequence of SEQ ID NO:2.

### Claim 34 (depends on 19)

The pharmaceutical composition of claim 19, wherein the galectin-7 protein includes a galectin-7 galactoside-binding domain.

### Claim 35

A method for the therapeutic treatment of epithelial wounds in mammals comprising administering to a mammal afflicted with an epithelial wound a therapeutically effective amount of a substance that influences the expression of epithelial cell surface receptors or receptors of the extracellular matrix.

### Claim 36

A method for the therapeutic treatment of epithelial wounds in mammals comprising administering to a mammal afflicted with an epithelial wound a therapeutically effective amount of a substance that influences the expression of a galectin-7 protein.

### Claim 37 (depends on 35, 36)

The method of claim 35 or 36, wherein said substance includes a galectin-3 protein with the amino acid sequence of SEQ ID NO:1.

### Claim 38 (depends on 35, 36)

The method of claim 35 or 36, wherein said substance includes a galectin-3 protein with an amino acid sequence that is substantially identical to the amino acid sequence of SEQ ID NO:1.
